Position of the Transparency Council – Trulicity (dulaglutide)
At its meeting on 4 November 2024, the Transparency Council adopted position No. 117/2024 on the evaluation of the drug Trulicity (dulaglutide) for the indication: type 2 diabetes
At its meeting on 4 November 2024, the Transparency Council adopted position No. 117/2024 on the evaluation of the drug Trulicity (dulaglutide) for the indication: type 2 diabetes